{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:38:53Z","timestamp":1784885933433,"version":"3.55.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":988,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim Danmark A\/S"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) is an increasing concern worldwide. A rising HF burden is expected due to the prospected future demographic changes with aging populations. Consequently, the long-term follow-up and treatment will be performed increasingly by primary care physicians in the future. Contemporary data on HF patients in primary care are needed to plan and ensure an effective and safe follow-up of future patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The electronic patient journals of 148 primary care clinics in Denmark were searched in a standardized manner to identify patients with HF [code K77 of the International Classification of Primary Care, Second Edition]. Prespecified variables including demographic information, clinical variables, co-morbidities, prescribed medications, and setting of follow-up were recorded. In total, 1111 patients were included in the study. The mean timepoint for the HF diagnosis was August 2018. In 95% of cases, the diagnosis of HF was made in a specialized setting. The echocardiogram data used for phenotyping were available in 1042 (94%) of the 1111 patients. HF with reduced ejection fraction (HFrEF) was present in 43%, recovered HFrEF in 31%, and HF with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) in 26%. In patients with HFrEF or recovered HFrEF, fundamental treatments were prescribed in 86% for angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or angiotensin receptor neprilysin inhibitor (ARNI), in 82% for beta-blocker, in 38% for mineralocorticoid receptor antagonist (MRA), and in 12% for sodium-glucose co-transporter-2 inhibitor (SGLT2i). Older patients were treated to a significantly lesser extent than young patients for all drug classes [odds ratio (OR) point estimates 0.50 to 0.69, all P-values &amp;lt; 0.05]. In patients with HFmrEF or HFpEF, an ACEI, ARB, or ARNI was prescribed in 67%, beta-blocker in 67%, MRA in 22%, and SGLT2i in 7.4% with significantly lower probability of treatment compared to patients with HFrEF or recovered HFrEF [OR point estimates 0.33 to 0.57, all P-values &amp;lt; 0.05]. The setting of follow-up was available in 96% of patients. Irrespective of HF phenotype, follow-up was performed solely in primary care in 64%. These patients were generally treated to a lesser extent with HF therapies compared with patients where follow-up included specialized care, yet differences were generally small.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HFrEF is the most common phenotype of HF in primary care followed by recovered HFrEF and fundamental therapies are markedly underutilized. Initiatives to increase the use of recommended therapies are needed to improve the future care of patients with HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14324","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T04:02:40Z","timestamp":1677556960000},"page":"1745-1756","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prevalence of Heart Failure Phenotypes and Current Use of Therapies in Primary Care: Results from a Nationwide Study"],"prefix":"10.1093","volume":"10","author":[{"given":"Jesper","family":"Jensen","sequence":"first","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte University Hospital , Hellerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael Kj\u00e6r","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Warrer","family":"Petersen","sequence":"additional","affiliation":[{"name":"General Practice, Gribskov L\u00e6gecenter , Gribskov ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Gerdes","sequence":"additional","affiliation":[{"name":"General Practice, L\u00e6ge Bo Gerdes , Hedehusene ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Rossing","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte University Hospital , Hellerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"2026012114101649300_ehf214324-bib-0001","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026012114101649300_ehf214324-bib-0002","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114101649300_ehf214324-bib-0003","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012114101649300_ehf214324-bib-0004","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ejhf.176","article-title":"Effect of extended follow-up in a specialized heart failure clinic on adherence to guideline recommended therapy: NorthStar adherence study","volume":"16","author":"Schou","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012114101649300_ehf214324-bib-0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ejhf.2418","article-title":"Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003-2017","volume":"24","author":"Zahir","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114101649300_ehf214324-bib-0006","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cardfail.2021.08.023","article-title":"Comparative effectiveness of dosing of medical therapy for heart failure: from the CHAMP-HF registry","volume":"28","author":"Greene","year":"2022","journal-title":"J Card Fail"},{"key":"2026012114101649300_ehf214324-bib-0007","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114101649300_ehf214324-bib-0008","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114101649300_ehf214324-bib-0009","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114101649300_ehf214324-bib-0010","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114101649300_ehf214324-bib-0011","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114101649300_ehf214324-bib-0012","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012114101649300_ehf214324-bib-0013","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamacardio.2016.1325","article-title":"Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction","volume":"1","author":"Kalogeropoulos","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026012114101649300_ehf214324-bib-0014","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","article-title":"Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012114101649300_ehf214324-bib-0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5603\/CJ.a2017.0103","article-title":"Heart failure with recovered ejection fraction: clinical characteristics, determinants and prognosis. CARDIOCHUS-CHOP registry","volume":"25","author":"Agra Bermejo","year":"2018","journal-title":"Cardiol J"},{"key":"2026012114101649300_ehf214324-bib-0016","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study","volume":"19","author":"Tsuji","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114101649300_ehf214324-bib-0017","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"2026012114101649300_ehf214324-bib-0018","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jchf.2022.01.020","article-title":"Clinical outcomes related to background diuretic use and new diuretic initiation in patients with HFrEF","volume":"10","author":"Curtain","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026012114101649300_ehf214324-bib-0019","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017765","article-title":"Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review","volume":"8","author":"Shanbhag","year":"2018","journal-title":"BMJ Open"},{"key":"2026012114101649300_ehf214324-bib-0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jchf.2021.12.004","article-title":"Frailty, guideline-directed medical therapy, and outcomes in HFrEF: from the GUIDE-IT trial","volume":"10","author":"Khan","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026012114101649300_ehf214324-bib-0021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/M21-4776","article-title":"Efficacy and safety of Dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial","volume":"175","author":"Butt","year":"2022","journal-title":"Ann Intern Med"},{"key":"2026012114101649300_ehf214324-bib-0022","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","article-title":"Efficacy and safety of Dapagliflozin according to frailty in patients with heart failure: a Prespecified analysis of the DELIVER trial","volume":"146","author":"Butt","year":"2022","journal-title":"Circulation"},{"key":"2026012114101649300_ehf214324-bib-0023","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080","article-title":"Efficacy and safety of Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial","volume":"15","author":"Peikert","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026012114101649300_ehf214324-bib-0024","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jacc.2022.06.037","article-title":"Sacubitril\/valsartan and frailty in patients with heart failure and preserved ejection fraction","volume":"80","author":"Butt","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012114101649300_ehf214324-bib-0025","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical Care in Diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice C","year":"2022","journal-title":"Diabetes Care"},{"key":"2026012114101649300_ehf214324-bib-0026","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/eurjhf\/hfq219","article-title":"Self-care management of heart failure: practical recommendations from the patient Care Committee of the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Lainscak","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026012114101649300_ehf214324-bib-0027","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026012114101649300_ehf214324-bib-0028","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/eurheartj\/ehs235","article-title":"Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar)","volume":"34","author":"Schou","year":"2013","journal-title":"Eur Heart J"},{"key":"2026012114101649300_ehf214324-bib-0029","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/ehjqcco\/qcab086","article-title":"Cardiac rehabilitation for patients with heart failure: association with readmission and mortality risk","volume":"8","author":"Thygesen","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026012114101649300_ehf214324-bib-0030","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2020-001369","article-title":"Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation","volume":"7","author":"Pallisgaard","year":"2020","journal-title":"Open Heart"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14324","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/1745\/65017680\/eschf_10_3_1745.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/1745\/65017680\/eschf_10_3_1745.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:11:30Z","timestamp":1769022690000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/3\/1745\/8304686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2,28]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14324","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"2022-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}